See more : Metro AG (B4B3.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Sumitomo Pharma Co., Ltd. (SMDPY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sumitomo Pharma Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- DeHua TB New Decoration Material Co.,Ltd (002043.SZ) Income Statement Analysis – Financial Results
- Culpeo Minerals Limited (CPO.AX) Income Statement Analysis – Financial Results
- PT. Verena Multi Finance Tbk (VRNA.JK) Income Statement Analysis – Financial Results
- Global Hunter Corp. (GBLHF) Income Statement Analysis – Financial Results
- Rich Sport Public Company Limited (RSP.BK) Income Statement Analysis – Financial Results
Sumitomo Pharma Co., Ltd. (SMDPY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sumitomo-pharma.com
About Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 314.56B | 555.54B | 560.04B | 515.95B | 482.73B | 459.27B | 466.84B | 411.65B | 403.21B | 371.37B | 387.71B | 347.73B | 350.38B | 379.53B | 296.30B | 264.06B | 263.99B | 261.21B | 245.78B | 175.09B |
| Cost of Revenue | 126.58B | 178.92B | 157.13B | 137.77B | 129.67B | 113.55B | 112.35B | 100.08B | 104.47B | 101.23B | 104.12B | 101.69B | 98.85B | 110.05B | 112.30B | 103.77B | 99.39B | 99.35B | 130.44B | 111.10B |
| Gross Profit | 187.98B | 376.63B | 402.91B | 378.18B | 353.06B | 345.71B | 354.49B | 311.57B | 298.74B | 270.14B | 283.59B | 246.04B | 251.54B | 269.48B | 184.00B | 160.30B | 164.61B | 161.87B | 115.35B | 63.99B |
| Gross Profit Ratio | 59.76% | 67.79% | 71.94% | 73.30% | 73.14% | 75.28% | 75.93% | 75.69% | 74.09% | 72.74% | 73.15% | 70.76% | 71.79% | 71.00% | 62.10% | 60.70% | 62.35% | 61.97% | 46.93% | 36.55% |
| Research & Development | 112.64B | 131.86B | 94.90B | 132.68B | 115.11B | 102.36B | 86.93B | 80.82B | 82.03B | 71.30B | 69.80B | 59.84B | 56.89B | 68.16B | 51.37B | 52.82B | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 429.54B | 373.32B | 249.08B | 190.37B | 154.35B | 180.44B | 183.65B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.13B | 4.96B | 4.84B | 5.15B | 124.79B | 116.31B | 86.46B | 52.40B |
| Selling & Marketing | 0.00 | 59.86B | 37.78B | 37.36B | 37.75B | 37.98B | 38.21B | 24.08B | 26.96B | 28.82B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 429.54B | 373.32B | 249.08B | 190.37B | 154.35B | 180.44B | 183.65B | 24.08B | 26.96B | 28.82B | 171.65B | 161.15B | 5.13B | 4.96B | 4.84B | 5.15B | 124.79B | 116.31B | 86.46B | 52.40B |
| Other Expenses | 0.00 | 0.00 | -1.31B | -16.10B | 360.00M | 5.03B | -4.26B | -802.00M | -749.00M | -1.58B | -1.60B | -1.29B | -756.00M | -1.35B | -1.41B | -651.00M | -1.00M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 542.18B | 453.60B | 342.67B | 306.96B | 269.82B | 287.83B | 266.32B | 258.81B | 261.80B | 246.86B | 241.45B | 220.99B | 126.12B | 138.88B | 76.88B | 74.65B | 124.79B | 116.31B | 86.46B | 52.40B |
| Cost & Expenses | 669.42B | 632.52B | 499.80B | 444.73B | 399.49B | 401.38B | 378.67B | 358.88B | 366.27B | 348.09B | 345.57B | 322.69B | 224.97B | 248.92B | 189.18B | 178.42B | 224.18B | 215.66B | 216.90B | 163.50B |
| Interest Income | 36.02B | 32.22B | 25.78B | 9.21B | 3.57B | 7.37B | 2.43B | 746.00M | 627.00M | 399.00M | 314.00M | 330.00M | 347.00M | 494.00M | 635.00M | 974.00M | 853.00M | 987.00M | 518.00M | 603.00M |
| Interest Expense | 4.28B | 3.16B | 3.05B | 2.59B | 2.86B | 207.00M | 5.74B | 631.00M | 919.00M | 937.00M | 1.01B | 1.07B | 1.12B | 1.92B | 1.02B | 93.00M | 127.00M | 108.00M | 91.00M | 62.00M |
| Depreciation & Amortization | 37.77B | 41.26B | 38.35B | 22.67B | 17.37B | 13.98B | 12.89B | 12.71B | 20.27B | 19.23B | 26.78B | 35.09B | 40.23B | 44.63B | 18.65B | 11.46B | 11.87B | 12.01B | 8.90B | 5.23B |
| EBITDA | -281.07B | -3.50B | 124.36B | 103.11B | 100.29B | 79.23B | 95.61B | 56.18B | 57.20B | 42.50B | 62.49B | 54.31B | 57.68B | 71.60B | 50.22B | 43.72B | 53.45B | 57.56B | 40.16B | 16.98B |
| EBITDA Ratio | -89.35% | -0.63% | 22.21% | 19.98% | 21.58% | 17.25% | 22.17% | 17.88% | 13.67% | 11.18% | 17.65% | 17.44% | 47.16% | 46.06% | 42.19% | 36.89% | 19.58% | 22.41% | 16.34% | 11.48% |
| Operating Income | -354.19B | -76.98B | 60.23B | 71.22B | 83.24B | 57.88B | 88.17B | 52.76B | 36.93B | 23.28B | 42.14B | 25.04B | 20.40B | 30.95B | 35.62B | 31.17B | 39.81B | 45.56B | 28.89B | 11.59B |
| Operating Income Ratio | -112.60% | -13.86% | 10.76% | 13.80% | 17.24% | 12.60% | 18.89% | 12.82% | 9.16% | 6.27% | 10.87% | 7.20% | 5.82% | 8.16% | 12.02% | 11.80% | 15.08% | 17.44% | 11.75% | 6.62% |
| Total Other Income/Expenses | 31.08B | 29.06B | 22.73B | 6.63B | 708.00M | 7.16B | -3.31B | 6.93B | 2.63B | 10.48B | -7.43B | -6.89B | -4.08B | -6.10B | -4.20B | 1.00B | 1.64B | -7.14B | -3.20B | 101.00M |
| Income Before Tax | -323.11B | -47.92B | 82.96B | 77.85B | 83.95B | 65.05B | 84.87B | 47.22B | 39.56B | 33.76B | 34.71B | 18.16B | 16.33B | 25.05B | 31.42B | 32.17B | 41.46B | 38.42B | 25.69B | 11.69B |
| Income Before Tax Ratio | -102.72% | -8.63% | 14.81% | 15.09% | 17.39% | 14.16% | 18.18% | 11.47% | 9.81% | 9.09% | 8.95% | 5.22% | 4.66% | 6.60% | 10.61% | 12.18% | 15.70% | 14.71% | 10.45% | 6.67% |
| Income Tax Expense | -8.19B | 48.79B | 42.36B | 41.02B | 48.03B | 16.42B | 31.42B | 18.23B | 14.86B | 18.31B | 14.65B | 8.11B | 7.70B | 8.25B | 10.46B | 12.17B | 15.79B | 15.75B | 10.24B | 4.67B |
| Net Income | -314.97B | -74.51B | 56.41B | 56.22B | 40.75B | 48.63B | 53.45B | 28.99B | 24.70B | 15.45B | 20.06B | 10.04B | 8.63B | 16.80B | 20.96B | 19.99B | 25.59B | 22.61B | 15.38B | 6.92B |
| Net Income Ratio | -100.13% | -13.41% | 10.07% | 10.90% | 8.44% | 10.59% | 11.45% | 7.04% | 6.13% | 4.16% | 5.17% | 2.89% | 2.46% | 4.43% | 7.07% | 7.57% | 9.69% | 8.65% | 6.26% | 3.95% |
| EPS | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 | 134.53 | 78.82 | 62.16 | 38.88 | 50.49 | 25.28 | 21.72 | 42.27 | 52.75 | 50.30 | 64.39 | 56.87 | 54.57 | 41.76 |
| EPS Diluted | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 | 134.53 | 78.82 | 62.16 | 38.88 | 50.49 | 25.28 | 21.72 | 42.27 | 52.75 | 50.30 | 64.39 | 56.87 | 54.57 | 41.76 |
| Weighted Avg Shares Out | 397.29M | 397.29M | 397.29M | 397.29M | 397.30M | 397.30M | 397.30M | 397.30M | 397.30M | 397.31M | 397.31M | 397.31M | 397.31M | 397.31M | 397.32M | 397.36M | 397.45M | 397.50M | 280.99M | 165.11M |
| Weighted Avg Shares Out (Dil) | 397.29M | 397.29M | 397.29M | 397.29M | 397.30M | 397.30M | 397.30M | 397.30M | 397.30M | 397.31M | 397.31M | 397.31M | 397.31M | 397.31M | 397.32M | 397.36M | 397.45M | 397.50M | 280.99M | 165.11M |
Source: https://incomestatements.info
Category: Stock Reports